ArticleScientific reports2019
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota.BMC microbiology · 2023Pooled it
- Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.Nature medicine · 2022Pooled it
- Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study.Frontiers in cellular and infection microbiology · 2026Trial
- MyBioScope: a new frontier in gut microbiome and health research.Bioresources and bioprocessing · 2026Article
- The role of Traditional Chinese Medicine in the management of liver disease: targeting gut microbiome.Chinese medicine · 2026Review
- Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosis.Cellular and molecular life sciences : CMLS · 2026Review
- Efficacy of very low calorie diet in the intervention of obesity and the changes in oral microbiota: a prospective cohort study.Journal of translational medicine · 2026Observational
- The oral microbiome as a regulatory hub for systemic health: a systematic review of mechanistic links and clinical implications.Journal of oral microbiology · 2026Review
- Gut oralisation signatures in Parkinson's disease: an integrative multi-study analysis.Journal of oral microbiology · 2026Article
- Research advances on gut microbiota dysbiosis and chronic liver diseases: a review.Frontiers in medicine · 2026Review
- Gut mucosa-associated microbiota signatures in healthy individuals and patients at different stages of liver disease: a pilot study.Gut pathogens · 2025Article
- Dietary Prebiotics Modulate Omeprazole-Induced Alterations in the Gut Microbial Signature.Molecular nutrition & food research · 2025Article
- Microbiome signatures of virulence in the oral-gut-brain axis influence Parkinson's disease and cognitive decline pathophysiology.Gut microbes · 2025Article
- Review
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
- Article
- Microbiome Landscape and Association with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors: A SCRUM-Japan MONSTAR-SCREEN Study.Cancer research communications · 2025Article
- Sucrose-preferring gut microbes prevent host obesity by producing exopolysaccharides.Nature communications · 2025Article
- Article
- Nitrogen recycling by the gut microbiome in sarcopenia.Frontiers in microbiology · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance benefits and risks of PPI therapy are largely missing. In this study, we tested gut-derived biomarkers to identify PPI-associated dysbiosis, its association with gut barrier function and liver-related mortality. In this observational study, faecal microbiome composition data obtained from 16S rDNA sequencing of 90 cirrhotic patients with and without long-term PPI use and additional potential biomarkers identified from the literature were evaluated for their predictive value regarding PPI-associated dysbiosis and liver-related three-year mortality. In addition, faecal calprotectin, faecal zonulin and serum lipopolysaccharides were assessed as markers for intestinal inflammation, gut permeability and bacterial translocation. Streptococcus salivarius, Veillonella parvula and the genus Streptococcus were significantly increased in patients with long-term PPI therapy and performed well as biomarkers for PPI-associated dysbiosis (accuracy: 74%, 72% and 74%, respectively). The abundance of Streptococcus salivarius was linked to intestinal inflammation and gut barrier dysfunction, whereas the abundance of Veillonella parvula showed associations with liver disease severity; both were independent predictors for liver-related three-year mortality. Gut-derived biomarkers of PPI-associated dysbiosis are linked to worse outcome and a potential option to evaluate the risks of adverse events during long-term PPI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.